2次元ヒト幹細胞由来心筋細胞における心収縮性調節療法の評価

Executive Industry Relevance

Quantitative evaluation of cardiac contractility modulation (CCM) in 2D hiPSC-derived cardiomyocytes enables predictive, human-relevant assessment of cardiac device effects at the earliest stages of device R&D. This platform supports mechanistic de-risking and target validation for cardiac electrophysiology devices, providing robust, reproducible data to inform portfolio advancement and regulatory submissions. The approach bridges discovery biology and translational device safety, reducing reliance on animal models and accelerating nonclinical decision-making.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct interrogation of cardiac device effects on human contractile function in vitro.
• Supports mechanistic de-risking by quantifying contractile response to electrophysiological modulation.
• Facilitates functional target validation for device-induced cardiac modulation.
• Provides predictive confidence for downstream device optimization and triage.

Screening & Assay Development

• Delivers standardized, reproducible contractility assays using hiPSC-CM monolayers on flexible hydrogels.
• Enables multiplexed readouts of contraction, calcium handling, and electrophysiology in a 48-well format.
• Supports assay scalability and platform reuse for diverse cardiac device candidates.
• Generates quantitative outputs suitable for comparative device evaluation.

Translational & Preclinical Research

• Aligns in vitro contractility data with disease-relevant human cardiac models, including patient-specific hiPSC-CMs.
• Enables translational biomarker development by linking device signals to functional cardiac outcomes.
• Supports risk-adjusted advancement decisions for device safety and performance testing.
• Reduces reliance on animal and early human studies by providing robust nonclinical data.

Pipeline & Workflow Integration

This method integrates into the cardiac device R&D continuum from early discovery through preclinical safety and performance assessment.

• Discovery Biology: Quantifies device-induced changes in contractility, clarifying mechanistic pathways and biological targets.
• Screening: Provides reproducible, quantitative contractility and calcium sensitivity data for device candidate comparison.
• Analytics: Outputs include contraction amplitude, kinetics, and calcium dependence, supporting statistical comparison across conditions.
• Translational Research: Enables disease modeling and patient-specific testing for translational continuity.
• Enterprise Reuse: Platform is adaptable for multiple device types and disease models, supporting broad R&D utility.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac device evaluation.
• Operational Value: Standardizes contractility assessment, enhances reproducibility, and supports high-throughput workflows.
• Strategic Value: Improves go/no-go decisions and capital allocation by providing robust nonclinical data.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of cardiac device candidates.

Implementation Considerations

• Requires expertise in hiPSC-CM culture, electrophysiology, and video-based contractility analysis.
• Needs access to flexible hydrogel substrates, environmental control chambers, and high-speed video microscopy.
• Demands cross-team standardization of assay protocols and analytical software.
• Adaptable to various disease models and patient-specific hiPSC-CMs for broader translational relevance.
• Dependent on robust cell health and reproducible monolayer formation for consistent outputs.

Biopharma FAQs